Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen

Cancer Research

Volumn 56, Issue 1, 1996, Pages 66-71

  Osborne, Martin R ^a   Hewer, Alan ^a   Hardcastle, Ian R ^a   Carmichael, Paul L ^a   Phillips, David H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGUANOSINE; DNA; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DNA ADDUCT; DRUG CARCINOGENICITY; DRUG DNA INTERACTION; DRUG ISOLATION; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; GENOTOXICITY; LIVER CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DEOXYGUANOSINE; DNA; DNA ADDUCTS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; RATS; TAMOXIFEN;

EID: 0030050137     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jordan, V. C. Overview from the international conference on long term tamoxifen therapy for breast cancer. J. Natl. Cancer Inst., 84: 231-234, 1992.
2. Hard, G C., Iatropoulos, M. J , Jordan, K., Radi, L , Kaltenberg, O P., Imondi, A. R., and Williams, G. M. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl CD(BR) rats. Cancer Res., 53: 4534-4541, 1993
3. Greaves, P., Goonetilleke, R , Nunn, G., Topham, J., and Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park-Wistar derived rats. Cancer Res., 53: 3919-3924, 1993.
4. Williams, G. M , Iatropoulos, M. J., Djordjevic, M V., and Kaltenberg, O P The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis (Lond.), 14: 315-317, 1993
5. Seoud, M. A-F., Johnson, J., and Weed, J. C. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol., 82: 165-169, 1993.
6. Powles, T J The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet, 340: 1145-1147, 1992.
7. Zito, R. Problems in breast cancer prevention and therapy by tamoxifen. J Exp. Clin. Cancer Res., 13: 99-102, 1994.
8. King, C. M. Tamoxifen and the induction of cancer. Carcinogenesis (Lond.), 16: 1449-1454, 1995.
9. White, I N. H , de Matteis, F , Davies, A., Smith, L. L , Crofton-Sleigh, C , Venitt, S , Hewer, A., and Phillips, D. H Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis (Lond.), 13: 2197-2203, 1992.
10. Han, X., and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52: 1360-1363, 1992.
11. Pathak, D. N., and Bodell, W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis (Lond.), 15: 529-532, 1994.
12. Pathak, D. N., Pongracz, K., and Bodell, W. J. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis (Lond), 16: 11-15, 1995.
13. Hemminki, K., Widlak, P., and Hou, S. M. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis (Lond.), 16: 1661-1664, 1995.
14. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. I., and Poon, G K. α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes Cancer Res , 54: 5518-5522, 1994.
15. Poon, G. K., Walter, B., Leaning, P. E., Horton, M N., and McCague, R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and in patients on long-term therapy for breast cancer. Drug Metab. Dispos , 23: 377-382, 1995
16. Foster, A. B., Jarman, M., Leung, O-T., McCague, R., Leclercq, G., and Devleeschouwer, N Hydroxy derivatives of tamoxifen. J. Med Chem., 28: 1491-1497, 1985.
17. Osborne, M. R , and Lawley, P. D. Alkylation of DNA by melphalan with special reference to adenine derivatives and adenine-guanine cross-linking. Chem.-Biol. Interact., 89: 49-60, 1993.
18. 5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis (Lond.), 75: 1487-1492, 1994.
19. Phillips, D. H., Hewer, A., and Grover, P. L. Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogenesis (Lond.), 7: 2071-2075, 1986.
20. 32P-postlabeling test for structurally diverse DNA adducts Carcinogenesis (Lond.), 7: 1543-1551, 1986.
21. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis (Lond.), 15: 2087-2094, 1994.
22. Sykes, P Nucleophilic substitution at a saturated carbon atom (Ch 3), pp 57-75. In A Guidebook to Mechanism in Organic Chemistry. London: Longman Group, 1965
23. Lawley, P. D. The spectra of purines., In: J. H. Lister (ed.), Fused Pyrimidines Part II: Purines, pp 439-528. New York. Wiley-Interscience, 1971.
24. Osborne, M. R , Beland, F A., Harvey, R. G , and Brookes, P The reaction of (±)-7α, 8β-dihydroxy-9β,10β-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene with DNA. Int. J. Cancer, 18: 362-368, 1976.
25. Tomasz, M. Novel assay of 7-alkylation of guanine residues in DNA Biochim. Biophys Acta, 213: 288-295, 1970
26. Davies, A. M., Marun, E. A , Jones, R. M., Kim, C K., Smith, L L., and White, I N. H. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis (Lond.), 16: 539-545, 1995.
27. Phillips, D. H., Hewer, A., White, I N. H., and Farmer, P. B. Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis (Lond.), 15: 793-795, 1994.
28. McCague, R., and Seago, A. Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite. E-1-[4-(2-dimethylaminoeraoxy)-phenyl]-1 2-diphenyl-1-buten-3-ol N-oxide. Biochem. Pharmacol., 35: 827-834, 1986.
29. Potter, G. A., McCague, R , and Jarman, M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis (Lond.), 15: 439-442, 1994.
30. Bain, R. R., and Jordan, V. C. Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy. Biochem. Pharmacol., 32: 373-375, 1983
31. Pongracz, K., Pathak, D. N., Nakamura, T., Burlingame, A. L., and Bodell, W. J. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res , 14: 3012-3015, 1995.
32. s-ethyl]tamoxifen. Carcinogenesis (Lond), 16: 683-688, 1995.
33. 6 atom of adenine as sites for covalent binding of metabolically activated 1′-hydroxysafrole to mouse liver DNA in vivo. Cancer Res , 41: 2664-2671, 1981